• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
DESCRIBE-AD: A novel classification framework for atopic dermatitis.描述性广告:一种用于特应性皮炎的新型分类框架。
J Am Acad Dermatol. 2022 Sep;87(3):541-550. doi: 10.1016/j.jaad.2021.10.058. Epub 2021 Nov 10.
2
The Heterogeneity of Atopic Dermatitis.特应性皮炎的异质性。
J Drugs Dermatol. 2022 Feb 1;21(2):172-176. doi: 10.36849/JDD.6408.
3
Definition of treatment goals in terms of clinician-reported disease severity and patient-reported outcomes in moderate-to-severe adult atopic dermatitis: a systematic review.中重度成人特应性皮炎的临床医生报告疾病严重程度和患者报告结局治疗目标的定义:系统评价。
Curr Med Res Opin. 2021 Aug;37(8):1295-1301. doi: 10.1080/03007995.2021.1933929. Epub 2021 Jun 11.
4
Review of the holistic management of pediatric atopic dermatitis.儿童特应性皮炎的整体管理综述。
Eur J Pediatr. 2022 Apr;181(4):1363-1370. doi: 10.1007/s00431-021-04341-3. Epub 2022 Jan 22.
5
Measuring Atopic Dermatitis Disease Severity: The Potential for Electronic Tools to Benefit Clinical Care.测量特应性皮炎疾病严重程度:电子工具在改善临床护理方面的潜力。
J Allergy Clin Immunol Pract. 2021 Apr;9(4):1473-1486.e2. doi: 10.1016/j.jaip.2021.02.027.
6
Guidelines of care for the management of atopic dermatitis: section 1. Diagnosis and assessment of atopic dermatitis.特应性皮炎管理指南:第 1 节。特应性皮炎的诊断和评估。
J Am Acad Dermatol. 2014 Feb;70(2):338-51. doi: 10.1016/j.jaad.2013.10.010. Epub 2013 Nov 27.
7
The Psychosocial Burden Associated With and Effective Treatment Approach for Atopic Dermatitis: A Literature Review.特应性皮炎的社会心理负担及有效治疗方法:文献综述。
J Drugs Dermatol. 2021 Oct 1;20(10):1046-1050. doi: 10.36849/JDD.6328.
8
Patient-Reported Disease Burden and Unmet Therapeutic Needs in Atopic Dermatitis.特应性皮炎患者报告的疾病负担和未满足的治疗需求。
J Drugs Dermatol. 2021 Nov 1;20(11):1222-1230. doi: 10.36849/jdd.6329.
9
Strategies for Successful Management of Severe Atopic Dermatitis.成功管理重度特应性皮炎的策略。
J Allergy Clin Immunol Pract. 2019 Jan;7(1):1-16. doi: 10.1016/j.jaip.2018.10.021.
10
Good practice intervention for clinical assessment and diagnosis of atopic dermatitis: Findings from the atopic dermatitis quality of care initiative.特应性皮炎护理质量倡议:临床评估和诊断特应性皮炎的良好实践干预措施。
Dermatol Ther. 2022 Mar;35(3):e15259. doi: 10.1111/dth.15259. Epub 2021 Dec 30.

引用本文的文献

1
Describing atopic dermatitis in real-world clinical practice: a retrospective health system analysis.描述现实世界临床实践中的特应性皮炎:一项回顾性卫生系统分析。
Arch Dermatol Res. 2025 Feb 7;317(1):365. doi: 10.1007/s00403-025-03892-x.
2
A Multidisciplinary Approach Is Beneficial in Atopic Dermatitis.多学科方法对特应性皮炎有益。
Dermatol Ther (Heidelb). 2024 Jun;14(6):1443-1455. doi: 10.1007/s13555-024-01185-1. Epub 2024 May 30.
3
Management of Patients Affected by Moderate-to-Severe Atopic Dermatitis with JAK Inhibitors in Real-World Clinical Practice: An Italian Delphi Consensus.真实世界临床实践中使用JAK抑制剂治疗中重度特应性皮炎患者:意大利德尔菲共识
Dermatol Ther (Heidelb). 2024 Apr;14(4):919-932. doi: 10.1007/s13555-024-01135-x. Epub 2024 Mar 21.
4
Ozonated Sunflower Oil (OSO) Alleviates Inflammatory Responses in Oxazolone-Induced Atopic Dermatitis (AD)-Like Mice and LPS-Treated RAW 264.7 Cells.臭氧葵花籽油(OSO)可减轻氧化苦参碱诱导的特应性皮炎(AD)样小鼠和脂多糖处理的 RAW 264.7 细胞的炎症反应。
J Microbiol Biotechnol. 2024 Apr 28;34(4):765-773. doi: 10.4014/jmb.2310.10037. Epub 2024 Jan 12.

本文引用的文献

1
A real-world study of the longitudinal course of skin pain in adult atopic dermatitis.一项关于成人特应性皮炎皮肤疼痛纵向病程的真实世界研究。
J Am Acad Dermatol. 2022 May;86(5):1123-1127. doi: 10.1016/j.jaad.2021.04.021. Epub 2021 Apr 16.
2
Association of Atopic Dermatitis Severity With Learning Disability in Children.儿童特应性皮炎严重程度与学习障碍的关联。
JAMA Dermatol. 2021 Apr 14;157(6):1-7. doi: 10.1001/jamadermatol.2021.0008.
3
Clinical phenotyping of atopic dermatitis using combined itch and lesional severity: A prospective observational study.采用联合瘙痒和皮损严重程度对特应性皮炎进行临床表型分析:一项前瞻性观察研究。
Ann Allergy Asthma Immunol. 2021 Jul;127(1):83-90.e2. doi: 10.1016/j.anai.2021.03.019. Epub 2021 Apr 2.
4
Dupilumab-induced phenotype switch from atopic dermatitis to psoriasis is characterized by de novo interleukin-17A expression: a case report.度普利尤单抗诱导的从特应性皮炎到银屑病的表型转换以从头表达白细胞介素-17A为特征:一例报告
Br J Dermatol. 2021 Aug;185(2):432-434. doi: 10.1111/bjd.20064. Epub 2021 May 4.
5
Reliability and Longitudinal Course of Itch/Scratch Severity in Adults With Atopic Dermatitis.特应性皮炎成人瘙痒/搔抓严重程度的可靠性和纵向病程。
Dermatitis. 2021 Oct 1;32(1S):S28-S32. doi: 10.1097/DER.0000000000000716.
6
Association of pediatric atopic dermatitis and psoriasis with school absenteeism and parental work absenteeism: A cross-sectional United States population-based study.儿童特应性皮炎和银屑病与缺课及父母缺勤的关联:一项基于美国人群的横断面研究。
J Am Acad Dermatol. 2021 Oct;85(4):885-892. doi: 10.1016/j.jaad.2021.02.069. Epub 2021 Mar 2.
7
Prevalence and trend of allergen sensitization in patients with nummular (discoid) eczema referred for patch testing: North American Contact Dermatitis Group data, 2001-2016.在因钱币状湿疹(盘状湿疹)接受斑贴试验而转诊的患者中,变应原致敏的流行率和趋势:北美接触性皮炎组数据,2001-2016 年。
Contact Dermatitis. 2021 Jul;85(1):46-57. doi: 10.1111/cod.13824. Epub 2021 Mar 16.
8
Validity and reliability of a novel numeric rating scale to measure skin-pain in adults with atopic dermatitis.一种用于测量成人特应性皮炎皮肤疼痛的新型数字评分量表的效度和信度。
Arch Dermatol Res. 2021 Dec;313(10):855-861. doi: 10.1007/s00403-021-02185-3. Epub 2021 Feb 6.
9
Recommended core outcome instruments for health-related quality of life, long-term control and itch intensity in atopic eczema trials: results of the HOME VII consensus meeting.特应性皮炎临床试验中与健康相关的生活质量、长期控制和瘙痒强度的推荐核心结局指标:HOME VII 共识会议的结果。
Br J Dermatol. 2021 Jul;185(1):139-146. doi: 10.1111/bjd.19751. Epub 2021 Feb 8.
10
Measurement Properties of Patient Health Questionnaire 9 and Patient Health Questionnaire 2 in Adult Patients With Atopic Dermatitis.患者健康问卷 9 项和患者健康问卷 2 项在特应性皮炎成年患者中的测量特性。
Dermatitis. 2021;32(4):225-231. doi: 10.1097/DER.0000000000000653.

描述性广告:一种用于特应性皮炎的新型分类框架。

DESCRIBE-AD: A novel classification framework for atopic dermatitis.

机构信息

Department of Dermatology, Feinberg School of Medicine at Northwestern University, Chicago, Illinois.

Department of Dermatology, The George Washington University School of Medicine and Health Sciences, Washington, DC.

出版信息

J Am Acad Dermatol. 2022 Sep;87(3):541-550. doi: 10.1016/j.jaad.2021.10.058. Epub 2021 Nov 10.

DOI:10.1016/j.jaad.2021.10.058
PMID:34774658
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10119387/
Abstract

BACKGROUND

Atopic dermatitis (AD) is a chronic, inflammatory skin disease associated with heterogeneous morphology, distribution, symptoms, severity, extent, longitudinal courses, quality of life burden, comorbidities, and treatment responses. This heterogeneity contributes to challenges in diagnosis, the characterization of disease activity, and therapeutic stratification.

OBJECTIVE

To develop a framework to standardize AD assessment.

METHODS

We propose a novel framework to assess AD based on a literature review and clinical experience.

RESULTS

DESCRIBE-AD is a framework that can effectively capture the clinical domains contributing to AD heterogeneity and includes both patient- and clinician-reported perspectives. DESCRIBE-AD includes assessments of Dermatitis morphology and phenotype, Evolution of disease, Symptom severity, Comorbid health disorders, Response to therapy, Intensity of lesions, Burden of disease, and Extent of lesions. Rather than placing the focus on any single, specific aspect of AD, DESCRIBE-AD allows for a comprehensive approach to the assessment and clinical management of AD.

CONCLUSIONS

DESCRIBE-AD is a novel framework that can be used to better describe the heterogeneity of AD and guide treatment decisions.

摘要

背景

特应性皮炎(AD)是一种慢性炎症性皮肤病,具有异质性的形态、分布、症状、严重程度、范围、纵向病程、生活质量负担、合并症和治疗反应。这种异质性导致诊断、疾病活动特征和治疗分层方面的挑战。

目的

制定一个标准化 AD 评估的框架。

方法

我们提出了一种新的基于文献回顾和临床经验的 AD 评估框架。

结果

DESCRIBE-AD 是一个能够有效捕捉导致 AD 异质性的临床领域的框架,包括患者和临床医生报告的观点。DESCRIBE-AD 包括对皮炎形态和表型、疾病演变、症状严重程度、合并健康障碍、治疗反应、病变强度、疾病负担和病变范围的评估。DESCRIBE-AD 不侧重于 AD 的任何单一特定方面,而是允许对 AD 的评估和临床管理采取全面的方法。

结论

DESCRIBE-AD 是一个新的框架,可以更好地描述 AD 的异质性,并指导治疗决策。